HLS Therapeutics (TSE:HLS) Sets New 12-Month High - Still a Buy?

Key Points

• HLS Therapeutics' stock reached a new 52-week high of C$5.65, outpacing the previous close, indicating positive market momentum.
• Raymond James Financial upgraded HLS Therapeutics from a "hold" to a "moderate buy" rating, with an increased price target of C$6.00.
• The company's market capitalization is C$179.57 million, with notable financial ratios including a debt-to-equity ratio of 86.50 and a PE ratio of -11.92.

HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The company traded as high as C$5.65 and last traded at C$5.60, with a volume of 4711 shares changing hands. The stock had previously closed at C$5.65.

Analyst Ratings Changes

Separately, Raymond James Financial upgraded shares of HLS Therapeutics from a "hold" rating to a "moderate buy" rating and lifted their price objective for the company from C$5.00 to C$6.00 in a research report on Thursday, August 21st. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of C$5.00.

HLS Therapeutics Stock Up 1.2%

The company has a market capitalization of C$179.57 million, a PE ratio of -11.92 and a beta of 0.65. The firm's 50-day simple moving average is C$5.09 and its 200 day simple moving average is C$4.71. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.